文献速递前列腺癌

影像学在早期复发性前列腺癌中作用的系统综述

A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2018-10-24

该系统综述检索 MEDLINE 和 EMBASE 至 2018 年 2 月,纳入 98 项研究,评估经直肠超声、CT、骨显像、多参数 MRI、全身 MRI 及多种 PET-CT/MRI 在复发 PSA ≤5 ng/ml 患者中的作用。不同影像技术的检出率取决于成像时的 PSA 水平,先进影像技术可能在 PSA 仍很低时检出复发灶。

要点

  • CT 和骨显像在早期复发场景中敏感性不足。
  • 复发 PSA <0.5 ng/ml 时,11C 胆碱 PET-CT 检出率可达 31.3%,68Ga PSMA-11 PET-CT 可达 65.0%。
  • 复发 PSA <0.2 ng/ml 时,68Ga PSMA-11 PET-CT 检出率为 11.3% 至 58.3%。

核心结论

  • 不同影像技术的检出率取决于成像时的 PSA 水平;近期先进影像技术可能在 PSA 水平仍很低时检出复发灶定位。

研究设计与样本

  • 系统综述,检索 MEDLINE 和 EMBASE 数据库,检索时间为 2018 年 2 月,纳入报告复发 PSA 水平不超过 5 ng/ml 患者(亚组)影像学研究的原始研究,共纳入 98 项研究,按 PRISMA 指南进行,采用 QUADAS-2 工具评估方法学质量。

主要发现

  • CT 和骨显像在早期复发场景中敏感性不足。
  • 检测局部复发可用经直肠超声或多参数 MRI;但在最低 PSA 水平时数据很少,仅根治性前列腺切除术后,阳性率范围宽。
  • 经直肠超声或多参数 MRI 需联合(PET)-CT 评估远处病变,而全身 MRI、PET-MRI 或 PET-CT 等新技术可实现一体化评估。
  • 复发 PSA <0.5 ng/ml 时,11C 胆碱 PET-CT 检出率可达 31.3%,68Ga PSMA-11 PET-CT 检出率可达 65.0%。
  • 复发 PSA <0.2 ng/ml 时,68Ga PSMA-11 PET-CT 检出率为 11.3% 至 58.3%。

关键数值与推荐

  • 复发 PSA <0.5 ng/ml 时,11C 胆碱 PET-CT 检出率可达 31.3%,68Ga PSMA-11 PET-CT 检出率可达 65.0%。
  • 复发 PSA <0.2 ng/ml 时,68Ga PSMA-11 PET-CT 检出率为 11.3% 至 58.3%。

临床怎么用

  • 检测局部复发可用经直肠超声或多参数 MRI;在最低 PSA 水平时数据很少,仅根治性前列腺切除术后,阳性率范围宽。
  • 经直肠超声或多参数 MRI 需联合(PET)-CT 评估远处病变,全身 MRI、PET-MRI 或 PET-CT 等新技术可实现一体化评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: In patients treated for prostate cancer, a rising serum prostate-specific antigen (PSA) level is a first sign of relapse, but imaging is needed to determine the localization of the recurrence, which may be local, in lymph nodes, and/or metastatic. With the increasing success rate of earlier salvage therapy, the diagnosis has become pertinent when the recurrent PSA level is still very low. OBJECTIVE: To systematically review the literature on the role of the existing imaging techniques in patients with early recurrent prostate cancer. EVIDENCE ACQUISITION: A systematic literature search across the MEDLINE and EMBASE databases was conducted in February 2018, searching for original studies reporting on imaging in a (sub)group of patients with recurrent PSA levels not higher than 5ng/ml. This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. The methodological quality of the studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool. EVIDENCE SYNTHESIS: A total of 98 studies were included in this systematic review, reporting on the role of transrectal ultrasonography (TRUS), computed tomography (CT), bone scintigraphy (BS), single-photon emission CT, multiparametric magnetic resonance imaging (mpMRI), whole-body MRI (wbMRI), and positron emission tomography (PET)-CT/MRI using 18F fluoro-deoxy-glucose, 11C choline, 18F (fluoro)(methyl)choline, 11C acetate, 18F FACBC (fluciclovine) and prostate-specific membrane antigen (PSMA)-based tracers. CT and BS were not sufficiently sensitive in the early recurrence setting. For the detection of local recurrence, TRUS or mpMRI can be used; however, at the lowest PSA levels, few data were available, only after radical prostatectomy, showing a wide range of positivity. TRUS or mpMRI need to be combined with (PET)-CT to assess distant disease, but new techniques such as wbMRI, PET-MRI, or PET-CT allow for an all-in-one approach. At recurrent PSA levels <0.5ng/ml, detection rates up to 31.3% were reported using 11C choline PET-CT and up to 65.0% using 68Ga PSMA-11 PET-CT. At recurrent PSA levels <0.2ng/ml, detection rates of 68Ga PSMA-11 PET-CT ranged from 11.3% to as high as 58.3%. CONCLUSIONS: Detection rates of different imaging techniques depend on the PSA level at the time of imaging. Recent advanced imaging techniques may detect the localization of the recurrence, even when the PSA levels are still very low. PATIENT SUMMARY: In patients treated for prostate cancer, a rising serum prostate-specific antigen (PSA) level is a sign of recurrence of the disease. Advanced imaging techniques may demonstrate the localization of the recurrence, even when the PSA levels are still very low.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. De Visschere PJL, Standaert C, Fütterer JJ, et al. A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer. Eur Urol Oncol. 2018. PMID: 30929846. doi:10.1016/j.euo.2018.09.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。